Skip to main content

Figure S1 from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder

Other
Li, R; Sexton, WJ; Dhillon, J; Berglund, A; Naidu, S; Borjas, G; Rose, K; Kim, Y; Wang, X; Conejo-Garcia, JR; Jain, RK; Poch, MA; Spiess, PE ...
September 16, 2024

<p>12-CK Score from RNA Sequencing</p>

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

DOI

Publication Date

September 16, 2024
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, R., Sexton, W. J., Dhillon, J., Berglund, A., Naidu, S., Borjas, G., … Zhang, J. (2024). Figure S1 from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. https://doi.org/10.1158/1078-0432.27033796
Li, Roger, Wade J. Sexton, Jasreman Dhillon, Anders Berglund, Shreyas Naidu, Gustavo Borjas, Kyle Rose, et al. “Figure S1 from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder,” September 16, 2024. https://doi.org/10.1158/1078-0432.27033796.
Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. Figure S1 from A Phase 2 Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. 2024.

DOI

Publication Date

September 16, 2024